Owing to its carcinogenic properties, benzene is one of the most important environmental air pollutants. We have applied a simple pharmacokinetic model to estimate the individual daily exposure of persons of the general population to benzene using their urinary excretion of S-phenylmercapturic acid as biomarker of exposure. On the basis of a non-representative convenience sample of the general population, spontaneous urine samples of 43 non-smoking persons, 13 persons with exposure to environmental tobacco smoke (ETS) (as determined by urinary cotinine) and 72 smokers were analyzed for S-phenylmercapturic acid, and benzene exposure was back calculated on the basis of the results. The pharmacokinetic model was based either on estimated daily urinary volume or creatinine excretion. Median daily exposure of non-smokers was calculated to be 47 mg/day (volume-based model) and 63 mg benzene/day (creatinine-based model). ETS-exposed persons had a slightly higher median daily exposure of 65 mg/day (volume-based model) and 72 mg benzene/day (creatinine-based model). The daily exposure of smokers was significantly higher with median values of 491 mg benzene/day (volumebased model) and 693 mg benzene/day (creatinine-based model). Our biomarker-based model gave plausible results for daily benzene exposure that were in good agreement with exposure estimations published earlier. As it is purely based on the determination of individual internal dose, our model provides a powerful tool for the risk assessment of environmental benzene.
Introduction
Benzene is a well-known genotoxic carcinogen and a natural component of crude oil and fuels. In the past, it has been extensively used as an industrial solvent or as an intermediate for chemical synthesis. Several international agencies have classified benzene as a known human carcinogen (IARC group 1) because of an excess risk of leukaemia and other blood disorders such as aplastic anaemia or myelodysplastic syndrome in workers with high exposure to benzene (IARC, 1987; Kim et al., 2007) . As acute effects of high occupational exposure to benzene neurotoxic symptoms such as dizziness, headache or nausea were reported (Duarte-Davidson et al., 2001) . Strict regulations in the use of benzene and exposure limits have led to a massive decline in occupational and environmental benzene exposure and the number of employees reporting acute symptoms. According to current law, benzene content in gasoline is restricted to a maximum of 1 vol.% in the European Union since 2000 (European Directive 98/70/EC).
Apart from its direct usage, benzene is also formed during incomplete combustion of fossil fuels (gasoline, coal, wood), so that it represents an ubiquitous environmental carcinogen with potential health effects to the general population. Continuous long-term exposure to low environmental concentrations of benzene is an issue of special public health concern, as several investigations so far reported positive associations between residence near potential hydrocarbon emission sources (e.g., oil raffineries) or indicators of automotive emissions and acute childhood leukaemia (Knox, 1994; Lyons et al., 1995; Sans et al., 1995; Knox and Gilman, 1997; Harrison et al., 1999; Wilkinson et al., 1999) . Moreover, five out of six case-control studies showed a positive association between different indicators of air pollution or heavy traffic in the vicinity of children's homes and acute leukaemia (Savitz and Feingold, 1989; Nordlinder and Jarvholm, 1997; Feychting et al., 1998; Harrison et al., 1999; Pearson et al., 2000; Raaschou-Nielsen et al., 2001; Langholz et al., 2002; Crosignani et al., 2004) , whereas in three of these studies, this association turned out to be significant (Nordlinder and Jarvholm, 1997; Pearson et al., 2000; Crosignani et al., 2004) .
Two recent French case-control studies also reported significantly positive associations for childhood acute leukaemia and living near or next to a gas station or automotive repair garage with an odds ratio of OR ¼ 1.6 (1.2-2.2) (Steffen et al., 2004; Brosselin et al., 2009 ). However, despite this strong evidence, a biological monitoring of benzene as one possible causative agent for leukaemia has not been conducted in any of the epidemiological studies mentioned.
Besides vehicle exhaust or evaporation from petrol, the most relevant source of exposure to benzene for the general population is environmental tobacco smoke (ETS) or active smoking habits. Tobacco mainstream smoke was reported to contain approximately 3-60 mg benzene/cigarette with an average of 40 mg/cigarette (Darall et al., 1998) . Furthermore, minor indoor sources for benzene might be emissions from copier machines or laser printers (Jungnickel et al., 2003) , and use of paints or floor adhesives (Rastogi, 1993) .
Consequently, industrial emissions and traffic exhaust originating from the burning of fossil fuels, evaporation of benzene from handling or storage of fuels as well as personal smoking habits or exposure to ETS are probably the main contributors to the exposure of the general population to benzene. In a survey in German households, indoor air levels for benzene have been reported to range from 2.2 to 5.9 mg/m 3 . The mean outdoor levels for benzene in this survey ranged from 1.3 to 9.6 mg/m 3 with the highest concentrations in urban surroundings (Schneider et al., 2001) . Similar outdoor concentrations were reported in a survey conducted in the United Kingdom with mean concentrations ranging from 1.3 to 8.0 mg/m 3 (summarized by DuarteDavidson et al., 2001) . To protect the public from possible health effects of benzene, the European Union has adopted a benchmark value of 5 mg/m 3 for mean annual benzene concentrations in outdoor air. This benchmark value has to be reached until the year 2010, and then will be further reduced (European Directive 2000/69/EC). Regarding the United States, very recent research discovered that the 3-year averages of ambient air concentrations of benzene in the United States were above the 10 À6 cancer risk level at most sites nationwide with a high degree of confidence, making benzene one of the most important air pollutants (McCarthy et al., 2006 (McCarthy et al., , 2009 .
For an effective risk assessment of the environmental exposure of the general population to toxicants such as benzene, knowledge of the absorbed dose is of crucial importance. Biological monitoring is up to now the only tool available that allows estimating the overall absorbed dose of humans on an individual basis and thus helps to identify high exposure populations.
The urinary mercapturic acid of benzene, S-phenylmercapturic acid (S-PMA), is formed after conjugation of the highly reactive benzene oxide with glutathione and has been repeatedly recommended as the most specific biomarker of exposure to benzene at low concentrations, as there is no other known source of S-PMA (in contrast to other urinary metabolites of benzene such as phenol or t,t-muconic acid) (Hoet et al., 2009) . A short metabolism scheme of benzene is shown in Figure 1 . The elimination half-life of urinary S-PMA after exposure to benzene is considerably longer than that for t,t-muconic acid and has been determined to be 9.1 ( ± 3.7) hours (Boogaard and van Sittert, 1995) .
Earlier methods described in the literature were usually not sensitive enough for the determination of background excretion of S-PMA in the non-smoking general population. Our earlier study has developed a highly sensitive and specific on-line LC/MS/MS-method with column-switching that allows the determination of urinary S-PMA resulting from environmental benzene exposures (Schettgen et al., 2008) . In this study, we have applied this method to 128 urine samples of a convenience sample of the German general population with no known occupational exposure to benzene and used these data to estimate their individual daily intake (DI) of this environmental carcinogen.
Materials and methods

Study Population
Spot urine samples were collected from local donors (n ¼ 128) of the general population with no known occupational exposure to benzene as ascertained by a short questionnaire (no laboratory staff, no filling station attendants). This study population mainly consisted of students, university employees or persons with former asbestos exposure that were examined in our institute within a research project for the early detection of asbestos-caused malignancies.
The urine samples were stored at À201C until analysis. All participants gave informed written consent about the donation of urine before participating in the study. Smoking status was determined from self-reporting when urine was donated and additionally verified by the determination of urinary cotinine using a specific GC/MS-method with an LOD of 1 mg/l (Mu¨ller, 2003) . Urinary creatinine was determined photometrically according to Larsen using a 96-well plate photometer (Larsen, 1972) .
According to the anamnestic information from the participants and the results for urinary cotinine as a specific biomarker of cigarette consumption or exposure to ETS, the collective was divided into three groups. The study population consisted of 43 non-smokers (26 male, 17 female) with a median age of 32 years, ranging from 21 to 59 years. The concentration of cotinine in urine of these non-smokers ranged from o1 to 10 mg/l with a median of 3.2 mg/l. Creatinine content of these urine samples ranged between 0.22 and 2.93 g/l (median: 0.99 g/l).
As a second group, 13 non-smoking persons (8 male, 5 female) with a median age of 25 years (range: 22-50 years) were considered to have been exposed to ETS as determined by urinary cotinine using a cut-off-value of 10 mg/l urine as recommended by the Deutsche Forschungsgemeinschaft (Mu¨ller, 2003) . Their urinary cotinine concentrations ranged from 11 to 39 mg/l with a median value of 16.3 mg/l. Creatinine content of these urine samples ranged between 0.24 and 2.60 g/l (median: 1.45 g/l).
Finally, 72 persons (61 male, 11 female) were smokers with a median age of 36 years, ranging from 19 to 68 years. The mean number of daily smoked cigarettes reported for these persons was 17 cigarettes/day, ranging from 2 to 30 cigarettes/day. Urinary cotinine levels in these urine samples ranged from 77 to 4300 mg/l with a median of 1638 mg/l. The creatinine content of the smokers' urine samples ranged from 0.25 to 3.58 g/l (median: 1.22 g/l).
Determination of Urinary S-PMA Urinary S-PMA was determined as described earlier using an automated column-switching LC/MS/MS-method (Schettgen et al., 2008) . In short, 1 ml of urine was transferred to a 1.8-ml HPLC-vial, spiked with d 5 -labelled S-PMA as internal standard and acidified with formic acid to pH 2. Sample preparation and cleanup is carried out automatically by online-enrichment of the analytes on a Restricted-AccessMaterial column (LiChrospher RP-8 ADS, Merck, Darmstadt, Germany), where proteins and large matrix components are eliminated. After transfer of the analytes to the analytical column (Luna C 8 (2), 150 Â 4.6 mm, Phenomenex, Aschaffenburg, Germany), they are further separated from matrix compounds and finally determined by tandem mass-spectrometry using deuterium-labelled S-PMA as internal standard on a Sciex API 3000 LC/MS/MS system in ESI-negative mode (Applied Biosystems, Darmstadt, Germany). The LOQ of the method was determined to be 0.05 mg/l urine, which is sufficient to determine the background excretion of S-PMA even in non-smoking persons. The precision between-series for urinary S-PMA was determined by spiking pooled urine with S-PMA in three concentrations (0.4-70 mg/l) and ranged from 3.4 to 12.2% (n ¼ 5 and n ¼ 8, respectively). Accuracy of our analysis is assured by regular successful participation in round robins (German External Quality Assessment Scheme, www.g-equas.de).
Calculation of DI of Benzene
We converted the excretion values of S-PMA to DI values for benzene applying the following equations that have already been applied for the calculation of phthalate intakes of the general population (David, 2000; Koch et al., 2003) .
These calculations have been based on urinary creatinine excretion according to the following formula:
In addition, we have calculated daily benzene uptake based on daily excreted urinary volume according to this formula:
These formulae are simplified approaches to estimate DIs based on urinary excretion (UE) rates and have also been applied by the German Commission on Human Biomonitoring (German Commission on Human Biomonitoring, 2007; Wittassek et al., 2007) . The urinary excretion (UE) of the benzene metabolite S-phenylmercapturic acid (S-PMA) in mg/g creatinine (or mg/l urine), CE is the daily creatinine excretion rate for women or men. UV is the daily urinary volume for women or men. Fractional urinary excretion (F UE ) is the percentage of benzene excreted as S-phenylmercapturic acid in humans. MW benzene and MW S-PMA are the molecular weights of benzene and S-phenylmercapturic acid (78.1 g/mol and 239.3 g/mol, respectively).
The daily CE was set to be 1.17 g creatinine/day for women and 1.80 g creatinine/day for men, daily UV was set to 1.13 l for women and 1.36 l for men as reported in the literature (Wissenschaftliche Tabellen Geigy, 1977) . Fractional UE data were provided by occupational studies where both personal air monitoring of benzene and UE of S-PMA was determined. The fraction of inhaled benzene excreted as S-PMA was calculated to be 0.0011 in the mean (Boogaard and van Sittert, 1995) , ranging from 0.0005 to 0.0026. This is in good agreement with the data of Kim et al. (2006) who reported an F UE for S-PMA below 0.01 without giving exact data. The DI values were calculated for each individual of our study group separately.
Results
Results for Urinary S-PMA in the Study Population
The results of biological monitoring in the study population are summarized in Table 1 on volume as well as on a creatinine basis. S-PMA was quantifiable in 38 of the 43 urine samples of non-smokers (88%) and 100% of the ETSexposed non-smokers as well as smokers' urine samples. The median level of S-PMA in non-smokers was 0.12 mg/l urine, ranging from o0.05 to 0.42 mg/l. The level of S-PMA in urine of ETS-exposed non-smokers was slightly higher with a median value of 0.16 mg/l, ranging from 0.06 to 0.34 mg/l. When compared on a volume-basis, ETS-exposed nonsmokers showed a significantly higher excretion of S-PMA (P ¼ 0.04, Mann-Whitney-U) than non-smokers. However, this difference is non-significant when comparing the creatinine-based excretions of both groups (median: 0.12 mg/g creatinine vs 0.14 mg/g creatinine; P ¼ 0.54, Mann-Whitney-U).
The concentrations of S-PMA in smokers' urine were about 10-fold higher compared with that of non-smokers with a median level of 1.27 mg/l (range: 0.17-12.7 mg/l). Figure 1 illustrates the levels for urinary S-PMA in non-smokers, ETSexposed non-smokers and smokers in a boxplot.
We could find a highly significant correlation between urinary cotinine and S-PMA (see Figure 2) . Based on the view of the scatter plot of urinary S-PMA versus cotinine, the plot resembles a mathematical function of non-linear effect, so we fitted the data using an exponential type of model. The mathematical equation for this regression is S-PMA (mg/l urine ¼ 0.599*e (Cotinine/1742.9) . Although many methods could be used to fit the observed non-linear effects, this exponential model was selected due to its good performance to fit the relation between S-PMA and Cotinine with a correlation coefficient of r ¼ 0.621 (Figure 3) . Table 1 . Results of the determination of urinary S-phenylmercapturic acid and cotinine in the study population, divided into non-smokers, ETS-exposed non-smokers and smokers. 
DI Estimates for Benzene
Estimated intakes of benzene were calculated separately based on estimated daily UV or daily excretion of creatinine as described for women and men in the literature. Table 2 illustrates these intake estimates for non-smokers and smokers in our collective.
Both estimation models gave quite consistent results with median daily benzene exposure of non-smokers ranging between 47 and 63 mg/day. The 95th percentile for the exposure of non-smokers was calculated as 109-170 mg benzene/day.
Assuming an average inhalation rate of 20 m 3 air/day, the present exposure calculations that are strictly based on the determination of human internal dose would represent an average daily benzene air concentration for these persons of 2.4-3.2 mg/m 3 (95th percentile: 5.4-8.5 mg/m 3 ). With respect to the present quantitative cancer risk estimates for inhalative exposure to benzene published by the US EPA, this estimated average daily exposure would correspond to a lifetime risk of 5.3 Â 10 À6 -2.5 Â 10 À5 for developing leukaemia (US EPA, 2003) . Exposure to ETS (as determined by urinary cotinine) only slightly increased the calculated DI of benzene with median values of 65-72 mg/day. However, the 95th percentile for the benzene exposure of ETS-exposed individuals is comparable with the 95th percentile of non-smokers with values of 113-137 mg/day, indicating that there are further exposure sources (apart from ETS) or influence factors for nonsmokers that contribute to the calculated benzene exposure.
The daily benzene intake of smokers isFaccording to their higher S-PMA-excretionFapproximately 10 times higher than that for non-smokers, and was calculated to be 490 and 690 mg/day as median. Assuming a similar environmental exposure for smokers as for non-smokers, the impact of smoking on daily benzene exposure is estimated to be approximately 440-650 mg/day as median. Under consideration of the mean cigarette intake of 17 cigarettes/day assessed for these smokers, one daily smoked cigarette would contribute to the daily exposure with approximately 26-38 mg benzene.
Discussion
Using a simplified pharmacokinetic model, we were able to calculate the exposure of a convenience sample of the general population to benzene based on the determination of individual internal dose assessed by biological monitoring. To our knowledge, this study represents the first approach to use data from biological monitoring to calculate individual exposure to benzene of non-occupationally exposed individuals.
The pharmacokinetic model used for our calculations has previously been applied to estimate the DI of di(2-ethylhexyl)phthalate (DEHP) in the general population based on the results of biological monitoring of secondary DEHP metabolites (Koch et al., 2003) . Despite its simplicity, a most recent re-evaluation with a more sophisticated model once again accentuated its merits for exposure estimation (Lorber et al., 2009) .
Overall, the results of our exposure calculations based on excretion of S-PMA (see Table 2 ) were in good agreement with previous exposure estimates for the general population based on ambient air results of benzene in the United Kingdom as reported by Duarte-Davidson et al. (2001) . According to their estimation, total daily dose of benzene ranged between 70 (rural surrounding) and 95 (urban Figure 3. Correlation between urinary cotinine and S-phenylmercapturic acid in the examined urine samples. This non-linear correlation was highly significant, indicating cigarette smoke to be the main source of exposure to benzene for active smokers. surrounding) mg/day for non-smokers, 116-122 mg/day for passive smokers and 516-819 mg/day for smokers (DuarteDavidson et al., 2001) . With respect to our results for daily benzene uptake for non-smokers, we also back calculated average daily benzene air concentrations (median: 2.4-3.2 mg/m 3 air; 95th percentile: 5.4-8.5 mg/m 3 ) that are in very good accordance with values previously published for benzene in indoor and outdoor air (Duarte-Davidson et al., 2001; Schneider et al., 2001) . It is also noteworthy that a recent study reported UEs of S-PMA for non-smoking traffic policemen (median: 0.42 mg/g creatinine) exposed to low concentrations of airborne benzene (median: 6.1 mg/m 3 ) that are comparable to the 95th percentile measured within our study for nonsmokers of the general population (see Table 1 ) (Manini et al., 2008) . This study was the first to show changes in urinary S-PMA at airborne benzene concentrations of only a few mg/m 3 and underlines again the validity of our exposure estimation.
Our results for daily benzene exposure of smokers (median: 491-653 mg/day) are within the same range than previously reported estimations (Duarte-Davidson et al., 2001 ). Also our calculation that a daily smoked cigarette would contribute to benzene exposure of smokers with approximately 26-38 mg/cigarette (considering their anamnestic informations on smoking habits) is in good agreement with reported benzene concentrations in mainstream smoke of cigarettes (Darall et al., 1998) . Consequently, the results of our calculations gave very plausible results for non-smoking and smoking persons of the general population that were in excellent accordance with data from the literature on benzene exposure.
However, it has to be emphasized that our study has clear strengths and limitations. One of the most important strengths of our study is that all calculations are based on the determination of internal dose of a large group of individuals measured as the excretion of a highly specific metabolite of benzene using an accurate, validated and highly sensitive analytical method. This gives our results a much higher degree of validity than exposure estimates that are based on ''average'' benzene concentrations in outdoor air (usually with limited data) and different exposure scenarios. Moreover, our results and calculations reflect the dose of benzene that has de facto entered the body and are therefore much more relevant for risk assessment of environmental benzene.
A major limitation of our study is that our study population cannot necessarily be regarded as being representative for the whole general population. Furthermore, the knowledge of different specific living circumstances of these persons (such as urban/rural residence, exposure to petrol while refueling, living in the vicinity of a petrol station and so on) remains unknown, as our questionnaire covered only basic items such as age, sex, smoking habits and profession. This lack of information is mainly due to the fact that most of these urine samples were initially collected within another project and were then re-examined for this study.
A minor shortcoming of our study concerns the lack of information about genetic polymorphisms that are relevant for benzene metabolism in our study participants. According to a recent study, variants of GSTT1 and GSTM1 have the most relevant impact on excretion of S-PMA in humans with two-to threefold ratios of variant/referent at low levels of exposure (Kim et al., 2007) . Polymorphisms of these enzymes might be responsible for some of the upper ''outliers'' in the investigated persons (see correlation in Figure 2 ) that also represent the upper percentiles of our calculated daily benzene exposure in smokers. Of course, future studies should also take into account the effect of these polymorphisms.
Despite these limitations, our pilot study results supported the plausibility of estimating exposure to benzene based on individual data from biological monitoring of persons of the general population. The success of this approach is mainly due to the low limit of detection achieved with our newly developed analytical method for the quantification of urinary S-PMA (Schettgen et al., 2008) .
Our promising first results highlight the need to apply our method and the introduced model in large environmental epidemiological studies such as the US National Health and Nutrition Examination Survey (NHANES) or the German Environmental Survey (GerES). In these surveys, much of the information lacking in our present pilot study are collected, so that the contribution of certain living circumstances to the individual exposure to benzene can be assessed and strategies to prevent and reduce the exposure to benzene for the (non-smoking) general population can be developed . With respect to the decreasing benchmark values for environmental benzene air concentrations within the current legislation in the European Union, such large-scale investigations would certainly improve the risk assessment of this environmental carcinogen and support the required strategies to minimize population exposures.
